Development of photodynamic therapy to early stage oral cancer using drug delivery system

使用药物输送系统开发早期口腔癌光动力疗法

基本信息

  • 批准号:
    11470438
  • 负责人:
  • 金额:
    $ 3.78万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

Photodynamic therapy (PDT) using both hematoporphyrin derivative (HPD) and photoradiation has had a high rate of effectiveness in combatting early stage cancers. We have studied, to apply this therapy to treatment of oral cancer, on verious type of cultured carcinoma cells derived from oral cancers.It has been revealed that squamous cell carcinoma cells (SCC) exhibited high sensitivity to PDT in comparison with salivary gland-derived adenocarcinoma cells (SAC). It became clear that SAC exhibited an increased level of reduced glutathion and glutathion peroxidase activity in comparison to those of SCC.The SCC which showed decreased sensitivity to PDT, exhibited a extremerly high level of glutathion S-transferase activity. Consequenly, the function of glutathion cascade were factors determining photosensitivity of the cells. In addition, the SCC demonstrated an increased intracellular level of drug compare to that SAC.So we have investigated lipid composition of cell-membrane of both cells under serum-free culture. It became evident that 60% of membrane lipids of SCC was phospholipids (PL) and 80% of those of SAC was neutral lipids (NL). The NL/PL ratio indicated that SCC showed low levels but SAC showed remarkably high levels. These result indicated that the cytotoxity of PDT correlated with the intracellular levels of drug resulted from the difference of membrane hydrophobicity.Thus, we have designed liposome which is comparable to the lipid composition of SCC cell membrane, constructed the liposome-entrapped anti-cancer drugs and examined sensitivity to this liposome of both SCC and SAC by growth assay. As the result, the liposome-entrapped drug exhibited enhanced cytotoxicity on SCC compare to either drug alone or drug-liposome mixture.
使用血卟啉衍生物(HPD)和光辐射的光动力疗法(PDT)在对抗早期癌症方面具有高效率。为了将这种疗法应用于口腔癌的治疗,我们对来自口腔癌的各种类型的培养癌细胞进行了研究,发现鳞状细胞癌细胞(SCC)对PDT的敏感性高于唾液腺来源的腺癌细胞(SAC)。很明显,SAC表现出减少谷胱甘肽和谷胱甘肽过氧化物酶活性的增加水平相比,SCC。SCC表现出对PDT的敏感性下降,表现出极高水平的谷胱甘肽S-转移酶活性。因此,谷胱甘肽级联反应的功能是决定细胞光敏性的因素。另外,SCC细胞内药物浓度较SAC高,因此我们在无血清培养条件下研究了SCC和SAC细胞膜的脂质组成。结果表明,SCC的膜脂中60%为磷脂(PL),SAC的膜脂中80%为中性脂(NL)。NL/PL比值表明SCC显示低水平,但SAC显示显著高水平。因此,我们设计了与SCC细胞膜脂质组成相似的脂质体,构建了脂质体包埋抗癌药物的脂质体,并通过生长实验检测了SCC和SAC对脂质体的敏感性。结果表明,脂质体包封的药物对SCC的细胞毒性比单独药物或药物-脂质体混合物增强。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Shigeaki TORATANI: "Effect of photodynamic action with pheophorbide-a on human oral carcinoma cells in serum-free culture."Tiss.Cult.Res.Commun.. 18・4. 345-352 (1999)
Shigeaki TORATANI:“脱镁叶绿酸-a 的光动力作用对无血清培养物中人口腔癌细胞的影响”。Tiss.Cult.Res.Commun. 18・4 (1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Toratani, S., Kimoto, N., Shinki, T.and Okamoto, T.: "Effect of photodynamic action with pheophorbide-a on human oral carcinoma cells in serum-free culture."Tiss.Cult.Res.Commun.. 18. 345-352 (1999)
Toratani, S.、Kimoto, N.、Shinki, T. 和 Okamoto, T.:“脱镁叶绿酸-a 的光动力作用对无血清培养物中人口腔癌细胞的影响。”Tiss.Cult.Res.Commun.
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Shigeaki TORATANI: "Effect of photodynamic action with pheophorbide-a on human oral carcinoma cells in serum-free culture."Tiss.Cult.Res.Commun.. 18. 345-352 (1999)
Shigeaki TORATANI:“脱镁叶绿酸-a 的光动力作用对无血清培养物中人口腔癌细胞的影响。”Tiss.Cult.Res.Commun.. 18. 345-352 (1999)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S. Toratani et al.: "Effect of photodynamic therapy action with pheophorbide-a on human oral carcinoma cells in serum-free culture"Tiss. Cult. Res. Commun.. 18・4. 345-352 (1999)
S. Toratani 等:“脱镁叶绿酸-a 对无血清培养物中的人口腔癌细胞的影响”Tiss Commun. 18・4 (1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TORATANI Shigeaki其他文献

TORATANI Shigeaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TORATANI Shigeaki', 18)}}的其他基金

Proteomic analysis of molecular-targeted therapy against KGFR of salivary gland carcinomas
唾液腺癌 KGFR 分子靶向治疗的蛋白质组学分析
  • 批准号:
    18592184
  • 财政年份:
    2006
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting therapy using specific difference of lipid composition of oral cancer cell, resistant
利用口腔癌细胞脂质成分的特异性差异开发靶向治疗,耐药
  • 批准号:
    13672098
  • 财政年份:
    2001
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New targeting therapy with complex of liposome, consist of comparable lipid composition of oral cancer cells, and anti-EGF receptor antibody.
采用脂质体复合物的新型靶向治疗,由口腔癌细胞的相似脂质成分和抗 EGF 受体抗体组成。
  • 批准号:
    10557191
  • 财政年份:
    1998
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new drug deliverty system with liposome consist of comparable to the lipid composition of oral cancer cancer cell membrane
开发新的脂质体药物递送系统,其组成与口腔癌癌细胞膜的脂质成分相当
  • 批准号:
    08672311
  • 财政年份:
    1996
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

Microbubble-ZPDGFRβ/PFD/liposome通过靶向肝星状细胞改善肿瘤微环境抑制肝细胞癌复发转移的作用及机制研究
  • 批准号:
    82272000
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
基于Gd-HPDO3A@Liposome-Ga-68的PET/MR用于肝肿瘤增强显像及酸碱微环境检测
  • 批准号:
    81701761
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
探索 ATR 和 PARP 抑制剂用于卵巢癌治疗:一种创新方法
  • 批准号:
    494635
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Operating Grants
Combination Therapy for Pancreatic Cancer
胰腺癌的联合治疗
  • 批准号:
    10581174
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
Combination of tumor targeted therapy with stroma modulating agent for PDAC
肿瘤靶向治疗与基质调节剂联合治疗 PDAC
  • 批准号:
    10629924
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy
用于改进结直肠癌免疫化疗的磷脂衍生纳米治疗平台
  • 批准号:
    10658146
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors
具有优先肺部靶向特性的定制纳米纤维可用于治疗转移性肺肿瘤
  • 批准号:
    10623913
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
Novel discovery of the antibody conjugated liposome for RAS/BRAF mutated colorectal and pancreatic cancers
针对 RAS/BRAF 突变结直肠癌和胰腺癌的抗体偶联脂质体的新发现
  • 批准号:
    23K15080
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
Developing a combinatorial treatment of CAR-T therapy and liposome-based mRNA vaccination for pediatric solid tumors
开发针对儿科实体瘤的 CAR-T 疗法和基于脂质体的 mRNA 疫苗接种的组合疗法
  • 批准号:
    23K07247
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
项目2:抑制AXL以改善子宫内膜癌的治疗反应
  • 批准号:
    10711637
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
Liposome fusion enabled extracellular vesicle detection for COVID-19
脂质体融合实现了 COVID-19 的细胞外囊泡检测
  • 批准号:
    10528030
  • 财政年份:
    2022
  • 资助金额:
    $ 3.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了